| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. A Webb, D Cunningham, JH Scarffe, P Harper, A Norman, JK Joffe, ... Journal of Clinical Oncology 15 (1), 261-267, 1997 | 1172 | 1997 |
| European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I S Krege, J Beyer, R Souchon, P Albers, W Albrecht, F Algaba, M Bamberg, ... European urology 53 (3), 478-496, 2008 | 779 | 2008 |
| European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) HJ Schmoll, R Souchon, S Krege, P Albers, J Beyer, C Kollmannsberger, ... Annals of Oncology 15 (9), 1377-1399, 2004 | 661 | 2004 |
| Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial RTD Oliver, MD Mason, GM Mead, H von der Maase, GJS Rustin, JK Joffe, ... The Lancet 366 (9482), 293-300, 2005 | 593* | 2005 |
| Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial JS Waters, A Norman, D Cunningham, JH Scarffe, A Webb, P Harper, ... British journal of cancer 80 (1), 269-272, 1999 | 413 | 1999 |
| Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study … RTD Oliver, GM Mead, GJS Rustin, JK Joffe, N Aass, R Coleman, R Gabe, ... Journal of Clinical Oncology 29 (8), 957-962, 2011 | 351 | 2011 |
| Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council … GJ Rustin, GM Mead, SP Stenning, PA Vasey, N Aass, RA Huddart, ... Journal of clinical oncology 25 (11), 1310-1315, 2007 | 211 | 2007 |
| Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a … RH Jones, A Casbard, M Carucci, C Cox, R Butler, F Alchami, TA Madden, ... The Lancet Oncology 21 (3), 345-357, 2020 | 209 | 2020 |
| Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up GM Mead, SD Fossa, RTD Oliver, JK Joffe, RA Huddart, JT Roberts, ... Journal of the National Cancer Institute 103 (3), 241-249, 2011 | 152 | 2011 |
| 18Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell … RA Huddart, MJ O'Doherty, A Padhani, GJS Rustin, GM Mead, JK Joffe, ... Journal of clinical oncology 25 (21), 3090-3095, 2007 | 140 | 2007 |
| Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. M Hill, A Norman, D Cunningham, M Findlay, V Nicolson, A Hill, A Iveson, ... Journal of clinical oncology 13 (6), 1297-1302, 1995 | 120 | 1995 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 112 | 2019 |
| Germ Cell Tumours V: The Proceedings of the Fifth Germ Cell Tumour Conference Devonshire Hall, University of Leeds, 13th–15th September, 2001 P Harnden, JK Joffe, WG Jones Springer Science & Business Media, 2012 | 112 | 2012 |
| A phase II study of interferon‐α, interleukin‐2 and 5‐fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation JK Joffe, RE Banks, MA Forbes, S Hallam, A Jenkins, PM Patel, GD Hall, ... British journal of urology 77 (5), 638-649, 1996 | 101 | 1996 |
| Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood K Pittman, S Burchill, J Southgate, J Joffe, M Gore, P Selby Annals of oncology 7 (3), 297-301, 1996 | 95 | 1996 |
| Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) RE Coleman, M Collinson, W Gregory, H Marshall, R Bell, D Dodwell, ... Journal of bone oncology 13, 123-135, 2018 | 93 | 2018 |
| Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone S Uday, CL Gaston, L Rogers, M Parry, J Joffe, J Pearson, D Sutton, ... The Journal of Clinical Endocrinology & Metabolism 103 (2), 596-603, 2018 | 68 | 2018 |
| Delay in the diagnosis of testicular tumours—changes over the past 18 years NS Vasudev, JK Joffe, C Cooke, F Richards, WG Jones British journal of general practice 54 (505), 595-597, 2004 | 59 | 2004 |
| Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK RA Watson, H De La Peña, MT Tsakok, J Joseph, S Stoneham, ... British Journal of Cancer 119 (9), 1044-1051, 2018 | 56 | 2018 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 54 | 2021 |
